{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:21:53Z","timestamp":1787062913244,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bloodstream infections (BSIs) are a leading cause of morbidity and mortality. The Improving Outcomes and Antimicrobial Stewardship study seeks to evaluate the impact of the Accelerate PhenoTest BC Kit (AXDX) on antimicrobial use and clinical outcomes in BSIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, quasiexperimental study compared clinical and antimicrobial stewardship metrics, prior to and after implementation of AXDX, to evaluate the impact this technology has on patients with BSIs. Laboratory and clinical data from hospitalized patients with BSIs (excluding contaminants) were compared between 2 arms, 1 that underwent testing on AXDX (post-AXDX) and 1 that underwent alternative organism identification and susceptibility testing (pre-AXDX). The primary outcomes were time to optimal therapy (TTOT) and 30-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 854 patients with BSIs (435 pre-AXDX, 419 post-AXDX) were included. Median TTOT was 17.2 hours shorter in the post-AXDX arm (23.7 hours) compared with the pre-AXDX arm (40.9 hours; P&amp;lt;.0001). Compared with pre-AXDX, median time to first antimicrobial modification (24.2 vs 13.9 hours; P&amp;lt;.0001) and first antimicrobial deescalation (36.0 vs 27.2 hours; P=.0004) were shorter in the post-AXDX arm. Mortality (8.7% pre-AXDX vs 6.0% post-AXDX), length of stay (7.0 pre-AXDX vs 6.5 days post-AXDX), and adverse drug events were not significantly different between arms. Length of stay was shorter in the post-AXDX arm (5.4 vs 6.4 days; P=.03) among patients with gram-negative bacteremia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For BSIs, use of AXDX was associated with significant decreases in TTOT, first antimicrobial modification, and time to antimicrobial deescalation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciab921","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T15:13:11Z","timestamp":1635174791000},"page":"269-277","source":"Crossref","is-referenced-by-count":28,"title":["Real-World Impact of the Accelerate PhenoTest BC Kit on Patients With Bloodstream Infections in the Improving Outcomes and Antimicrobial Stewardship Study: A Quasiexperimental Multicenter Study"],"prefix":"10.1093","volume":"75","author":[{"given":"Amira A","family":"Bhalodi","sequence":"first","affiliation":[{"name":"Scientific Affairs, Accelerate Diagnostics Inc , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-2270","authenticated-orcid":false,"given":"Shawn H","family":"MacVane","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Accelerate Diagnostics Inc , Tucson, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Iowa Hospitals and Clinics , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Ince","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Iowa Hospitals and Clinics , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Kinn","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, The University of Iowa Hospitals and Clinics , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M","family":"Percival","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, The University of Iowa Hospitals and Clinics , Iowa City, Iowa , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek N","family":"Bremmer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Allegheny Health Network, Allegheny General Hospital , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin R","family":"Carr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Allegheny Health Network, Allegheny General Hospital , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-7776","authenticated-orcid":false,"given":"Thomas L","family":"Walsh","sequence":"additional","affiliation":[{"name":"Department of Medicine and Division of Infectious Diseases, Allegheny Health Network, Allegheny General Hospital , Pittsburgh, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah M","family":"Bhatti","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A","family":"Shelburne","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, MD Anderson Cancer Center , Houston, Texas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romney M","family":"Humphries","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Accelerate Diagnostics Inc , Tucson, Arizona , USA"},{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences , Little Rock, Arkansas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences , Little Rock, Arkansas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan K","family":"Dare","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Arkansas for Medical Sciences , Little Rock, Arkansas , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Kolev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Madhusudhan","sequence":"additional","affiliation":[{"name":"Department of Hospital Epidemiology, Cedars-Sinai Medical Center , Los Angeles, California , USA and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Ben-Aderet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margie A","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center , Los Angeles, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"2022082520472717000_CIT0001","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/cit498","article-title":"Impact of rapid organism identification via matrix-assisted laser desorption\/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemia.","volume":"57","author":"Huang","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022082520472717000_CIT0002","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jinf.2014.05.005","article-title":"Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant gram-negative bacteremia.","volume":"69","author":"Perez","year":"2014","journal-title":"J Infect"},{"key":"2022082520472717000_CIT0003","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/cid\/civ447","article-title":"Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing.","volume":"61","author":"Banerjee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022082520472717000_CIT0004","article-title":"Randomized trial evaluating clinical impact of RAPid IDentification and susceptibility testing for gram negative bacteremia (RAPIDS-GN).","author":"Banerjee","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022082520472717000_CIT0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00578-20","article-title":"Pharmacist-driven implementation of fast identification and antimicrobial susceptibility testing improves outcomes for patients with gram-negative bacteremia and candidemia.","volume":"64","author":"Sheth","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082520472717000_CIT0006","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s15010-021-01601-0","article-title":"Impact of an antimicrobial stewardship program-bundled initiative utilizing accelerate Pheno\u2122 system in the management of patients with aerobic gram-negative bacilli bacteremia.","volume":"49","author":"Walsh","year":"2021","journal-title":"Infection"},{"key":"2022082520472717000_CIT0007","doi-asserted-by":"crossref","first-page":"e4616","DOI":"10.1093\/cid\/ciaa649","article-title":"Clinical impact of accelerate Pheno\u2122 rapid blood culture detection system in bacteremic patients.","volume":"73","author":"Dare","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022082520472717000_CIT0008","first-page":"1285","article-title":"Clinical impact of rapid species identification from positive blood cultures with same-day phenotypic antimicrobial susceptibility testing on the management and outcome of bloodstream infections.","volume":"70","author":"Ehren","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022082520472717000_CIT0009","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02364-20","article-title":"Impact of accelerate Pheno and BacT\/Alert virtuo on clinical processes and outcomes in patients with sepsis and concurrent gram-negative bacteremia.","volume":"65","author":"Babowicz","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022082520472717000_CIT0010","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkab165","article-title":"Improving outcomes and antibiotic stewardship (IOAS) for patients with gram-positive bloodstream infections through use of rapid testing: a quasi-experimental multicentre study of the Accelerate PhenoTestTM BC Kit.","author":"MacVane","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022082520472717000_CIT0011","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jiac.2015.08.019","article-title":"Prospective intervention study with a microarray-based, multiplexed, automated molecular diagnosis instrument (Verigene system) for the rapid diagnosis of bloodstream infections, and its impact on the clinical outcomes.","volume":"21","author":"Suzuki","year":"2015","journal-title":"J Infect Chemother"},{"key":"2022082520472717000_CIT0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1473-3099(20)30477-1","article-title":"Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals.","volume":"21","author":"Kadri","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022082520472717000_CIT0013","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjmed.2006.03.034","article-title":"Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay.","volume":"119","author":"Fraser","year":"2006","journal-title":"Am J Med"},{"key":"2022082520472717000_CIT0014","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1128\/JCM.02395-16","article-title":"Assessment of rapid-blood-culture-identification result interpretation and antibiotic prescribing practices.","volume":"55","author":"Donner","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2022082520472717000_CIT0015","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1007\/s00134-015-4016-6","article-title":"Antimicrobial de-escalation in septic cancer patients: is it safe to back down?.","volume":"41","author":"Paskovaty","year":"2015","journal-title":"Intensive Care Med"},{"key":"2022082520472717000_CIT0016","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00095-17","article-title":"The cost-effectiveness of rapid diagnostic testing for the diagnosis of bloodstream infections with or without antimicrobial stewardship.","volume":"31","author":"Pliakos","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"2022082520472717000_CIT0017","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1128\/JCM.00996-16","article-title":"Benefits of adding a rapid PCR-based blood culture identification panel to an established antimicrobial stewardship program.","volume":"54","author":"MacVane","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2022082520472717000_CIT0018","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab921\/41785782\/ciab921.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/2\/269\/45537420\/ciab921.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/75\/2\/269\/45537420\/ciab921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T16:47:46Z","timestamp":1661446066000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/75\/2\/269\/6412757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,27]]},"published-print":{"date-parts":[[2022,8,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab921","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,15]]},"published":{"date-parts":[[2021,10,27]]}}}